

DAFTAR PUSTAKA

1. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Vol. 97, Postgraduate Medical Journal. BMJ Publishing Group; 2021. p. 312–20.
2. WHO (2022). WHO Global. <https://covid19.who.int/> - Diakses Juni 2022.
3. Kemenkes RI (2022). Data Sebaran COVID-19 Indonesia. <https://covid19.go.id/> - Diakses Juni 2022.
4. Ochani RK, Kumar Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Vol. 20, *Le Infezioni in Medicina*, n. 2021.
5. Pradhan M, Shah K, Alexander A, Ajazuddin, Minz S, Singh MR, et al. COVID-19: clinical presentation and detection methods. *J Immunoassay Immunochem*. 2022 Jan 2;43(1).
6. Müller-Wieland D, Marx N, Dreher M, Fritzen K, Schnell O. COVID-19 and Cardiovascular Comorbidities. *Experimental and Clinical Endocrinology & Diabetes*. 2022 Mar 6;130(03):178–89.
7. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. *J Infect Public Health*. 2020 Dec;13(12):1833–9.
8. Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. *Am J Infect Control*. 2021 Feb;49(2):238–46.
9. Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. *European Journal of Clinical Microbiology & Infectious Diseases*. 2021 May 3;40(5):905–19.
10. Gasmi A, Peana M, Pivina L, Srinath S, Gasmi Benahmed A, Semenova Y, et al. Interrelations between COVID-19 and other disorders. *Clinical Immunology*. 2021 Mar;224:108651.
11. Mahendradhata Y, Andayani NLPE, Hasri ET, Arifi MD, Siahaan RGM, Solikha DA, et al. The Capacity of the Indonesian Healthcare System to Respond to COVID-19. *Front Public Health*. 2021 Jul 7;9.
12. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Buku Pedoman Tatalaksana COVID-19. 4th ed. Burhan E, Susanto AD, Isbaniah F, Nasution SA, Ginanjar E, Pitoyo CW, et al., editors. Jakarta: PDPI, PERKI, PAPDI, PERDATIN, IDAI; 2022.
13. Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H, et al. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. *Scand J Immunol*. 2021 Apr;93(4):e12998.
14. Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis —A review of current methods. *Biosens Bioelectron*. 2021 Jan;172:112752.
15. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. *Journal of the Chinese Medical Association*. 2020 Mar;83(3):217–20.
16. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. *Journal of Community Empowerment for Health*. 2020 Aug 6;3(2):77.

17. Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: Vulnerability, immunity and intervention. *Ageing Res Rev.* 2021 Jan;65:101205.
18. Cai R, Zhang J, Zhu Y, Liu L, Liu Y, He Q. Mortality in chronic kidney disease patients with COVID-19: a systematic review and meta-analysis. *Int Urol Nephrol.* 2021 Aug 3;53(8):1623–9.
19. Infeksi Emerging Kementerian Kesehatan RI (2023). Dashboard Situasi COVID-19. <https://infeksiemerging.kemkes.go.id/dashboard/covid-19> - Diakses Februari 2023.
20. Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. *BMJ Open.* 2021 Jan 11;11(1):e044640.
21. Zhang J jin, Dong X, Liu G hui, Gao Y dong. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. *Clin Rev Allergy Immunol.* 2022 Jan 19;64(1):90–107.
22. Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. *Expert Rev Anti Infect Ther.* 2021 Jul 3;19(7):877–88.
23. Uddin M, Mustafa F, Rizvi TA, Loney T, al Suwaidi H, Al-Marzouqi AHH, et al. SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. *Viruses.* 2020 May 10;12(5):526.
24. Chilamakuri R, Agarwal S. COVID-19: Characteristics and Therapeutics. *Cells.* 2021 Jan 21;10(2):206.
25. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. *Viruses.* 2020 Mar 27;12(4):372.
26. Trougakos IP, Stamatelopoulos K, Terpos E, Tsitsilonis OE, Aivalioti E, Paraskevis D, et al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. *J Biomed Sci.* 2021 Dec 12;28(1):9.
27. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2022.
28. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. *Clinical Immunology.* 2020 Jun;215:108427.
29. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol.* 2021 Mar 6;19(3):141–54.
30. Peeling RW, Heymann DL, Teo YY, Garcia PJ. Diagnostics for COVID-19: moving from pandemic response to control. *The Lancet.* 2022 Feb;399(10326):757–68.
31. Alsharif W, Qurashi A. Effectiveness of COVID-19 diagnosis and management tools: A review. *Radiography.* 2021 May;27(2):682–7.
32. Sharma A, Balda S, Apreja M, Kataria K, Capalash N, Sharma P. COVID-19 Diagnosis: Current and Future Techniques. *Int J Biol Macromol.* 2021 Dec;193:1835–44.
33. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, et al. Tools and Techniques for Severe Acute Respiratory

- Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. *Clin Microbiol Rev.* 2021 Jun 16;34(3).
34. Gallo G, Calvez V, Savoia C. Hypertension and COVID-19: Current Evidence and Perspectives. *High Blood Pressure & Cardiovascular Prevention.* 2022 Mar 20;29(2):115–23.
 35. Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. *Hypertension Research.* 2020 Aug 1;43(8):824–31.
 36. Peng M, He J, Xue Y, Yang X, Liu S, Gong Z. Role of Hypertension on the Severity of COVID-19: A Review. *J Cardiovasc Pharmacol.* 2021 Nov;78(5):e648–55.
 37. Govender N, Khaliq OP, Moodley J, Naicker T. Insulin resistance in COVID-19 and diabetes. *Prim Care Diabetes.* 2021 Aug;15(4):629–34.
 38. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. *Diabetes Res Clin Pract.* 2020 Apr;162:108142.
 39. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat Rev Endocrinol.* 2021 Jan 13;17(1):11–30.
 40. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA.* 2020 Mar 17;323(11):1061.
 41. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol.* 2020 Jul 1;5(7):811.
 42. Szarpak L, Mierzejewska M, Jurek J, Kochanowska A, Gasecka A, Truszewski Z, et al. Effect of Coronary Artery Disease on COVID-19—Prognosis and Risk Assessment: A Systematic Review and Meta-Analysis. *Biology (Basel).* 2022 Jan 29;11(2):221.
 43. Loffi M, Piccolo R, Regazzoni V, di Tano G, Moschini L, Robba D, et al. Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection. *Open Heart.* 2020 Nov 23;7(2):e001428.
 44. Carlson N, Nelveg-Kristensen K -E., Freese Ballegaard E, Feldt-Rasmussen B, Hornum M, Kamper A -Lise, et al. Increased vulnerability to COVID-19 in chronic kidney disease. *J Intern Med.* 2021 Jul 10;290(1):166–78.
 45. Bhinder OS, Swarnim S, Mantan M, Dabas A, Ahlawat RS. Chronic Kidney Disease and COVID-19: Outcomes of hospitalised adults from a tertiary care centre in North India. *Med J Armed Forces India.* 2022 Feb;
 46. Saunders MJ, Evans CA. COVID-19, tuberculosis and poverty: preventing a perfect storm. *European Respiratory Journal.* 2020 Jul;56(1):2001348.
 47. Centers for Disease Control and Prevention (2020). Tuberculosis and Public Health Emergencies. <https://www.cdc.gov/tb/education/public-healthemergencies.htm> - Diakses Maret 2023.
 48. Purohit D, Ahirwar AK, Sakarde A, Asia P, Gopal N. COVID-19 and lung pathologies. *Horm Mol Biol Clin Investig.* 2021 Dec 8;42(4):435–43.
 49. Higham A, Mathioudakis A, Vestbo J, Singh D. COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. *European Respiratory Review.* 2020 Dec 31;29(158):200199.

50. Petrakis D, Margină D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality (Review). *Mol Med Rep.* 2020 May 5;22(1):9–19.
51. de Leeuw AJM, Oude Luttikhuis MAM, Wellen AC, Müller C, Calkhoven CF. Obesity and its impact on COVID-19. *J Mol Med.* 2021 Jul 6;99(7):899–915.
52. Gammone MA, D’Orazio N. COVID-19 and Obesity: Overlapping of Two Pandemics. *Obes Facts.* 2021;14(6):579–85.
53. Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during Pregnancy and Possible Vertical Transmission. *Am J Perinatol.* 2020 Jun 18;37(08):861–5.
54. Rasmussen SA, Jamieson DJ. COVID-19 and Pregnancy. *Infect Dis Clin North Am.* 2022 Jun;36(2):423–33.
55. Dashraath P, Wong JJJ, Lim MXK, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. *Am J Obstet Gynecol.* 2020 Jun;222(6):521–31.
56. Jamieson DJ, Rasmussen SA. An update on COVID-19 and pregnancy. *Am J Obstet Gynecol.* 2022 Feb;226(2):177–86.
57. Brown LB, Spinelli MA, Gandhi M. The interplay between HIV and COVID-19: summary of the data and responses to date. *Curr Opin HIV AIDS.* 2021 Jan;16(1):63–73.
58. Spinelli MA, Jones BLH, Gandhi M. COVID-19 Outcomes and Risk Factors Among People Living with HIV. *Curr HIV/AIDS Rep.* 2022 Oct 5;19(5):425–32.
59. Al-Quteimat OM, Amer AM. The Impact of the COVID-19 Pandemic on Cancer Patients. *Am J Clin Oncol.* 2020 Jun;43(6):452–5.
60. Zong Z, Wei Y, Ren J, Zhang L, Zhou F. The intersection of COVID-19 and cancer: signaling pathways and treatment implications. *Mol Cancer.* 2021 Dec 17;20(1):76.
61. Hajjar LA, Costa IBS da S, Rizk SI, Biselli B, Gomes BR, Bittar CS, et al. Intensive care management of patients with COVID-19: a practical approach. *Ann Intensive Care.* 2021 Dec 18;11(1):36.
62. Menkes RI. 2010. Keputusan Menteri Kesehatan Republik Indonesia Nomor 834/Menkes/SK/VII/2010 Tentang Pedoman Penyelenggaraan Pelayanan High Care Unit (HCU) di Rumah Sakit.
63. Dahlan MS. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. 3rd ed. Jakarta: Salemba Medika; 2010.
64. Maharani D, Maulidya Sari S, Arsyad M. Epidemiological Description of Covid-19 for the January-July 2021 Period at the Cempaka Putih Health Center. *Jurnal Indonesia Sosial Sains.* 2023 Feb 20;4(02):106–12.
65. Tsani MII, Mafiana R, Dalilah. Karakteristik Pasien COVID-19 di Intensive Care Unit RSUP Dr. Mohammad Hoesin Palembang Periode Januari-Juni 2021. [Palembang]: Universitas Sriwijaya; 2021.
66. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA Intern Med.* 2020 Oct 1;180(10):1345.

67. Abate BB, Kassie AM, Kassaw MW, Aragie TG, Masresha SA. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. *BMJ Open*. 2020 Oct 6;10(10):e040129.
68. Lipsky MS, Hung M. Men and COVID-19: A Pathophysiologic Review. *Am J Mens Health*. 2020 Sep 16;14(5):155798832095402.
69. Tanjung H, Julizar J, Ermayanti S, Herman D, Mahata LE, Putra SP. Profil Pasien COVID-19 dengan Komorbid yang Dirawat di RSUP Dr. M. Djamil Padang. *Jurnal Ilmu Kesehatan Indonesia*. 2023 Mar 30;4(1):41–50.
70. Wulandari. “Profil Rasio Neutrofil Limfosit (Neutrophil Lymphocyte Ratio/ NLR) dan Rasio Trombosit Limfosit (Platelet Lymphocyte Ratio/ PLR) pada Pasien COVID-19 Klinis Kritis di ICU COVID RSUP. DR. M. Djamil Padang Periode 1 Agustus 2021 – 31 Maret 2022. [Padang]: Universitas Andalas; 2023.
71. Khaerunnisa R, Rumana NA, Yulia N, Fannya P. Gambaran Karakteristik Pasien Covid-19 di Rumah Sakit Mekar Sari Bekasi Tahun 2020-2021. *Jurnal Manajemen Informasi Kesehatan Indonesia*. 2022 Mar 2;10(1):72.
72. Wen S, Prasad A, Freeland K, Podury S, Patel J, Subedi R, et al. Clinical Characteristics and Outcomes of COVID-19 in West Virginia. *Viruses*. 2021 May 5;13(5):835.
73. Azwar MK, Setiati S, Rizka A, Fitriana I, Saldi SRF, Safitri ED. Clinical Profile of Elderly Patients with COVID-19 hospitalised in Indonesia’s National General Hospital. *Acta Med Indones*. 2020 Jul;52(3):199–205.
74. Cen Y, Chen X, Shen Y, Zhang XH, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—a multi-centre observational study. *Clinical Microbiology and Infection*. 2020 Sep;26(9):1242–7.
75. CNBC Indonesia (2021). Penuh Pasien COVID-19, ICU di Jabodetabek Terisi 100%. <https://www.cnbcindonesia.com/news/20210106125932-4-213863/penuh-pasien-covid-19-icu-di-jabodetabek-terisi-100> - Diakses Juli 2023.
76. CNBC Indonesia (2021). ICU Penuh Pasien COVID-19, Ini Saran dari Guru Besar FK UI. <https://www.cnbcindonesia.com/news/20210105164339-4-213676/icu-penuh-pasien-covid-19-ini-saran-dari-guru-besar-fk-ui> - Diakses Juli 2023.
77. Sprung CL, Joynt GM, Christian MD, Truog RD, Rello J, Nates JL. Adult ICU Triage During the Coronavirus Disease 2019 Pandemic: Who Will Live and Who Will Die? Recommendations to Improve Survival*. *Crit Care Med*. 2020 Aug 6;48(8):1196–202.
78. Vinay R, Baumann H, Biller-Andorno N. Ethics of ICU triage during COVID-19. *Br Med Bull*. 2021 Jun 10;138(1):5–15.
79. Akinosoglou K, Schinas G, Almyroudi MP, Gogos C, Dimopoulos G. The impact of age on intensive care. *Ageing Res Rev*. 2023 Feb;84:101832.
80. Ariani P. Hubungan Kadar C-Reactive Protein, Kadar Feritin, dengan Luaran Pada Pasien Coronavirus Disease 2019 di Intensive Care Unit COVID RSUP. Dr. M. Djamil Padang Periode Juli – Desember 2021. [Padang]: Universitas Andalas; 2023.

81. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Intervirology*. 2021;64(1):36–47.
82. Martins-Filho PR, Tavares CSS, Santos VS. Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. *Eur J Intern Med*. 2020 Jun;76:97–9.
83. Savoia C, Volpe M, Kreutz R. Hypertension, a Moving Target in COVID-19. *Circ Res*. 2021 Apr 2;128(7):1062–79.
84. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2020 Jul;14(4):535–45.
85. Pranata R, Henrina J, Raffaello WM, Lawrensia S, Huang I. Diabetes and COVID-19: The past, the present, and the future. *Metabolism*. 2021 Aug;121:154814.
86. Hessami A, Shamshirian A, Heydari K, Pourali F, Alizadeh-Navaei R, Moosazadeh M, et al. Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. *Am J Emerg Med*. 2021 Aug;46:382–91.
87. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med*. 2020 Apr;8(4):e21.

